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ABSTRACT Lactoferrin (LF), a glycoprotein present in
milk and other secretions, may provide a nutritional ingre-
dient for the treatment of intestinal disorders associated
with hyperpermeability, oxidative stress and inflammation.
The aim of the study was to determine the survival rate of
orally administered recombinant human lactoferrin (rhLF) in
the upper gastrointestinal (GI) tract and in the small intes-
tine in vivo in humans. Female ileostomy patients [n  8;
median age 44 (43–57) y] ingested a test beverage contain-
ing 5 g rhLF and collected full ileostomy output for 24 h. The
passage of the test beverage was monitored using radio-
opaque markers. Intact LF in ileal effluent was quantified by
ELISA. The entire test beverage passed the small bowel
during the 24-h ileal effluent collection period. LF was ex-
creted at a low but constant rate [0.35 (0.28–0.47) g LF/2
h]. Gastrointestinal passage of the test beverage and LF
excretion over time in the ileal effluent were not correlated.
In total, a median of 4 g LF was excreted over the 24-h
collection period, whereas 5 g rhLF was ingested. Hence,
dietary rhLF is digested in the upper GI tract and does not
reach the colon. Intact LF appearing in ileostomy effluent is
likely to originate from an endogenous source. J. Nutr.
132: 2597–2600, 2002.
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Lactoferrin (LF)3 is a protein of the transferrin family. It is
present in milk, saliva, tears, bile, blood plasma, mucosal and
genital secretions. LF is able to bind ferric iron (Fe3) with a
high affinity at two different lobes. A number of physiologic
effects have been attributed to LF. Previous studies have
shown bactericidal (1–4), anti-inflammatory (5), antiviral
(6–8) and antioxidative properties (9–11) of the LF molecule.
It has been suggested that LF has an anti-inflammatory
potential. This effect seems to be mediated in part by atten-
uating tumor necrosis factor (TNF)- response (12). TNF- is
involved in the pathogenesis of inflammatory bowel disease
(IBD) (13). Hence, from a theoretical point of view, LF could
potentially be used as an anti-inflammatory agent in the treat-
ment of IBD. An anti-inflammatory effect would be expected
after topical mucosal administration of the drug as in mesaza-
line and controlled ileal released budesonide therapy.
It is not known to what extent LF is degraded in the
gastrointestinal (GI) tract in vivo in adults. Digestion may
lessen the bioactivity of LF in the intestine. Oral LF supple-
mentation may provide a nutritional tool to improve gut
health especially the colon in humans. However, to exert any
effects in the colon, LF has to survive upper GI transit. If it is
digested in the stomach or in the small intestine, LF degrada-
tion should be prevented by the use of ileal release capsules or
by administration via enemas when studying its effects in the
colon.
We showed previously that LF is only partly degraded in the
stomach in vivo in adults (14). The metabolic fate of orally
ingested LF in the small intestine has not been investigated in
vivo in adults previously. The present study was designed to
determine the survival rate of orally administered recombinant
human lactoferrin (rhLF) in the upper GI tract and in the
small intestine in vivo in humans using the ileostomy model
and to quantify the amounts of LF entering the colon in vivo.
MATERIALS AND METHODS
Study 1. Lactoferrin supplementation
Subjects. Female volunteers (n  8) with an ileostomy [median
age 44 (43–57) y] participated in the study. In all women, a total
colectomy was performed at least 3 y before participation, enabling a
steady-state situation after the initial adaptation phase to the colec-
tomy. Women with Crohn’s disease were permitted to participate in
the study only if they had been in remission during the previous 3 y
and if  7.5% of the entire ileum was removed during previous
surgery. None of the women were taking any medication or had any
known abnormalities of the digestive system apart from the absence
of the colon. All of the women were informed about the aims and the
protocol of the study orally and in writing and they signed a written
informed consent before participation. The study was approved by the
Ethics Committee of the University Hospital Maastricht (Maastricht,
The Netherlands).
Dietary restriction. Subjects were not allowed to consume any
dairy products on the day before and on the day of the investigation
to avoid dietary LF intake. They had to consume a standardized diet
on each occasion. During breakfast at 0800 h and during lunch at
1300 h on the day before testing, they could consume bread rolls of
any kind and nondairy beverages ad libitum. Dinner at 1800 h was a
1 Supported by Agennix Incorporated, Houston, TX.
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prepared meal, consisting mainly of chow mein (Dinner 2 today,
Bami Goreng, Honig, Koog a/d Zaan, The Netherlands). On the day
of testing, the women were not allowed to consume any food until
breakfast at 1000 h. Subsequently, the diet was the same as described
for the day before testing.
Protocol. After an overnight fast, subjects were admitted to the
laboratory at 0800 h. They drank a test beverage containing 5 g rhLF
(produced by Aspergillus awamori, Agennix, Houston, TX) dissolved
in 0.10 L demineralized water. Immediately after ingestion of the test
beverage, the stoma effluent bag was discarded as performed routinely.
During the following 14 h, all stoma effluent was collected by replac-
ing the stoma bag at 2-h intervals. Each stoma bag was placed
separately in a small plastic airtight box on dry ice. Stoma effluent was
collected every 2 h during the daytime until 2200 h. Subsequently,
the women collected ileal effluent at 0300 and 0800 h.
Twenty radio-opaque plastic pellets (Sitzmarks Ø 2 mm, Konsyl
Pharmaceuticals Fort Worth, TX) were added to the test beverage of
each woman for a total of 160 pellets. These inert pellets can not be
absorbed from the lumen and hence provide a marker for test bever-
age recovery in the ileal effluent.
Measurements. After collection, each ileostomy effluent sample
was weighed to determine each 2-h and total 24-h ileal effluent
production. All samples were X-rayed to count the number of radio-
opaque pellets in each sample, which reflects the GI transit of the test
beverage. In the ileostomy effluent samples, the amount of intact LF
was determined by ELISA (Lactof-EIA, Biotech, Oxisresearch, Port-
land, OR). The CV of repeated measurements of this assay was 6%
as measured in spiked ileal effluent samples. The sensitivity of the
assay was 1 g/L. Data were expressed as LF excretion over 2-h
periods.
Study 2. Basal endogenous lactoferrin levels
In an additional in vivo pilot experiment, the endogenous LF
excretion from the small intestine was investigated. On a separate
day, four of the above-mentioned women collected ileal effluent
during the last 5 h of the night. Emptying of the ileostomy bag at
0300 h is common practice for most ileostomy patients. Ileal
effluent collection took place from 0300 to 0800 h. On the day
before this collection, subjects consumed the same diet as during the
first in vivo study. In a subsample of these ileal effluent samples, the
LF concentration was measured by ELISA as described above.
Statistics. The amount of intact LF excreted in the ileal effluent
during the 24-h period was expressed as LF excretion over 2-h
intervals. Differences were assessed using the Wilcoxon signed rank
test. Differences with P  0.05 were considered significant. The
median (10th–90th percentiles) ileal effluent production and LF
excretion at each time point were calculated and presented as Box-
and-Whisker displays.
RESULTS
Study 1. Lactoferrin supplementation
Of the 160 total plastic radio-opaque pellets ingested with
the test beverage (pooled over all experiments), 157 were
excreted in the ileal effluents over the 24-h collection period.
During the first 2 h after ingestion, no pellets were excreted. In
the ileal effluent samples collected from 4 to 10 h after inges-
tion of the test beverage, 147 pellets were emptied into the
stoma bags, whereas only 10 were excreted into the bags
during the following 9 h. During the last 5-h collection period,
no radio-opaque pellets were excreted (Table 1).
Ileal effluent production did not differ among any of the 2-h
collection periods. The median total ileal effluent production
over the 24-h collection period was 616 (456–865) g (Fig. 1).
The LF content of the ileal effluent samples did not differ
among any of the samples. The median 2-h LF excretion was
0.35 (0.28–0.47) g (Fig. 2). In total, a median of 4.01
TABLE 1
Excretion of radio-opaque pellets in the ileal effluent as an
indicator of test beverage recovery after passage through the
gastrointestinal tract of female ileostomists1
Time of ileal
effluent collection, h
Cumulative radio-opaque
pellets recovered, n
0–2 0
2–4 32
4–6 72
6–8 108
8–10 147
10–12 150
12–14 154
14–19 157
19–24 0
1 Eight women ingested a test beverage containing 20 radio-
opaque pellets for a total of 160 pellets.
FIGURE 1 Ileal effluent production (24-h) of eight female ileost-
omists after ingestion of 5 g recombinant human lactoferrin. Medians
(25th–75th percentiles) are displayed in boxes, 10th–90th percentiles
are displayed in whiskers. Ileal effluent was produced at a constant rate
during the collection period.
FIGURE 2 Ileal lactoferrin excretion (24-h) of eight female ileost-
omists after ingestion of 5 g recombinant human lactoferrin. Medians
(25th–75th percentiles) are displayed in boxes, 10th–90th percentiles
are displayed in whiskers. Low concentrations of recombinant or native
human lactoferrin appeared in the ileal effluent at a constant rate.
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(2.75–9.97) g LF was excreted over the 24-h period by each
woman (Table 2). The excretion of LF and the recovery of the
radio-opaque pellets were not correlated.
Study 2. Basal endogenous lactoferrin levels
In the absence of LF ingestion, the 5-h ileal effluents of the
four ileostomy patients contained 33 (24–52) g LF/L ileos-
tomy fluid. In the LF supplementation study, these subjects
had a median 5-h ileal effluent LF concentration of 7 (6–9)
g/L.
DISCUSSION
Small amounts of intact LF appeared in the ileostomy
effluent after oral ingestion of a LF-containing solution. The
LF was excreted at a constant rate over the 24-h collection
period. The recovery of the transit markers of the test beverage
and LF excretion in the ileal effluent were not correlated.
Most if not all of the LF present in bile and intestinal
secretions originates from specific granules of activated neu-
trophils (15–17). Plasma LF is secreted through bile into the
intestine (18). In healthy adults, biliary LF is 1 mg/L, and is
3 mg/L in patients with IBD (17). Additionally, fecal LF is
used as a diagnostic marker for immune system activation and
hence, disease activity, in IBD patients (19). In the feces of
healthy volunteers with an intact GI tract, LF excretion was
210 g/d, whereas patients with inactive ulcerative colitis or
inactive Crohn’s disease excreted 5–6 mg/d (19). In the
present study we found a median LF production of 4 g/d in
ileostomists. The discrepancy between these observations can
be explained by the hypothesis that the major part of LF in the
GI tract originates from leukocytes in the colon. This seems to
be a plausible conclusion because leukocytes are the major
source of LF. We propose that the LF excreted in the ileal
effluent may have originated from an endogenous source, not
from the diet.
This was confirmed by the second in vivo study in which
the women did not ingest LF, yet the ileal effluent samples had
the same or higher LF concentrations than the samples col-
lected over the same time period during the LF supplementa-
tion study. The effluent LF concentrations in the two studies
did not differ significantly. Although only four subjects par-
ticipated in the second study, we conclude that the LF de-
tected in ileal effluents in both studies originated from an
endogenous source.
The observation that orally ingested LF does not survive
passage through the small bowel confirms the findings of a LF
breakdown study in the small bowel in rats (20). In that study,
it was shown that during GI digestion of bovine LF, smaller
fragments that exert biological activity against fungi are
formed (21) and bacteria (3). This implies that although LF is
digested completely in the upper GI tract and in the small
intestine, oral LF ingestion may exert effects at any site in the
GI tract through the action of LF fragments. We could not
study the appearance of these fragments in the ileal effluent
because of technical limitations in the quantitative analysis of
LF fragments in the complex ileal effluent-matrix. Moreover,
the present study does not exclude any biological activity of
intact LF in the upper GI tract before degradation.
The rate of radio-opaque pellet excretion clearly showed
that the test beverage was emptied from the small intestine
within the 24-h ileal effluent collection period. This confirms
the validity of the ileostomy model for studying GI survival of
nutrients as we did in this study. Incomplete recovery of the
markers was observed on two occasions. The omission of two
markers in the ileal effluent of one volunteer and of one
marker in another volunteer may have been caused by a solid
particle that was retained temporarily in an intestinal fold. We
conclude that the test beverage was completely emptied from
the small intestine during the 24-h collection period.
The ileostomy model was used because it offered a unique
chance to collect complete ileal effluent after the full transit of
the test beverage through the upper GI tract. Hence, the
bioavailability of any nutrient from the diet to the colon can
be assessed. It is a well accepted method with which to study
the digestion of nutrients and extrapolate the findings to
subjects with an intact GI tract because the ileostomy patients
participating in the present study have an intact upper diges-
tive system.
A prerequisite for this technique of studying LF digestion in
the GI tract in ileostomists is the stability of LF ex vivo after
emptying into the ileostoma bag. LF may stay in the bag for a
maximum of 2 h. Digestion may continue in the bag. There-
fore we studied ex vivo LF degradation in ileal effluent. We did
not observe any LF degradation during 2 h of incubation in
fresh ileal effluent at 37°C (data not shown). This is consistent
with a previous report in which no degradation of LF was
observed during 2 h of incubation at 37°C in feces of healthy
volunteers (19).
We studied digestion of recombinant human LF, produced
in A. awamori. From three-dimensional structure comparisons
it was shown that this type of rhLF has the same three-
dimensional structure as the native human LF present in
human breast milk (22). Dynamic properties of recombinant
and native human LF are also similar. The only difference
between the two LF forms is the composition of the glycans
attached to the molecule due to the fungal system in which the
rhLF is produced (23). The ELISA method used for quantifi-
cation of intact LF present in the ileal effluent detected native
human as well as rhLF.
Iron binding was shown previously to affect the stability of
the LF molecule. Iron-saturated LF (holoLF) is more resistant
to degradation than iron-free LF (apoLF) (24,25). The rhLF
studied in the present study was free of iron. This is in contrast
with studies using apoLF of animal origin in the natural state,
which has an iron saturation of 15–20% (26). Therefore, the
rhLF used in the present study may be more susceptible to GI
degradation than LF of animal origin.
We showed that rhLF is completely degraded during pas-
sage through the stomach and the small intestine in vivo in
humans. Intact LF entering the colon is unlikely to originate
from an exogenous, dietary source of LF. This LF probably
TABLE 2
Lactoferrin excretion in the ileal effluent after oral ingestion of
5 g recombinant human lactoferrin in female ileostomists1
Time of ileal effluent
collection, h
Cumulative lactoferrin
in ileal effluent, g
0–2 0.39 (0.27–1.37)
2–4 0.61 (0.42–2.02)
4–6 0.89 (0.73–2.97)
6–8 1.34 (0.97–3.53)
8–10 1.82 (1.18–3.88)
10–12 1.99 (1.63–4.61)
12–14 2.22 (2.02–5.26)
14–19 2.95 (2.24–8.77)
19–24 4.01 (2.75–9.97)
1 Values are medians (25th–75th percentiles), n  8.
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originates from granules of activated neutrophils in the upper
GI tract. Therefore, if oral administration of LF does exert an
effect in the colon, LF should be encapsulated for ileal release
to prevent its degradation in the GI before it enters the colon.
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